14 Amendments of Marion WALSMANN related to 2021/2013(INI)
Amendment 3 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses the importance of developing a newat the EU pharmaceutical strategy which is consistent with the Union’s competences under the Treaties and with the principles of proportionality and subsidiarity, as a means of stimulating the development of European enterprises and making them competitive at global level and of guaranteeing better prevention and preparedness and more effective responses to future health emergenciess to build a stronger European Health Union in particular by supporting closer EU cooperation in research and development and by sharing health data;
Amendment 11 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Stresses that R&D is key for the development of innovative medicines, therapies and diagnosis;
Amendment 17 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Highlights that supporting the competitiveness and innovative capacity of the EU’s pharmaceutical industry is crucial;
Amendment 20 #
Draft opinion
Paragraph 1 d (new)
Paragraph 1 d (new)
1d. Welcomes the Commission’s Action Plan on Intellectual Property which shall help companies, especially small and medium-sized companies (SMEs), to make the most of their inventions and creations and ensure they can benefit our economy and society and which aims at enabling the European innovative industry to remain a global leader;
Amendment 22 #
Draft opinion
Paragraph 1 e (new)
Paragraph 1 e (new)
1e. Fully supports the IP Action Plan proposal to upgrade a series of existing IP tools and make them fit for the digital age, including improving the supplementary protection certificates (SPC) for patented medicinal products among other;
Amendment 23 #
Draft opinion
Paragraph 1 f (new)
Paragraph 1 f (new)
1f. Recalls the Council conclusions ‘An EU Industrial Policy Strategy: a Vision for 2030’ of May 2019 recognising that a well-functioning and effective intellectual property rights regime is key to continued development and growth and recalling that it is essential to continue developing, improving and updating the European intellectual property frameworks, so as to ensure that ideas and inventions can be effectively developed and brought to the market, in particular by and for SMEs, to the benefit of the European economy and society at large;
Amendment 24 #
Draft opinion
Paragraph 1 g (new)
Paragraph 1 g (new)
1g. Recalls the European Commission’s ‘Updating the 2020 New Industrial Strategy: Building a stronger Single Market for Europe’s recovery’ of May 2021 which states that the EU is strategically dependent on third countries regarding pharmaceutical ingredients and other health related products, which could lead to vulnerabilities for the EU and affect the EU’s core interests, and refers to the pharmaceutical strategy to address these issues;
Amendment 48 #
Draft opinion
Paragraph 3
Paragraph 3
3. Stresses the importance of facilitating and supporting research in the EU, not least in orderin order to be world market leader in improving existing and developing new medicines which could then lead to an increase of the number of patents filed in the Member States in this area; stresses that one of the priorities should be to develop medicines in areas where needs have been met only insufficiently or not at all or where commercial interest is low; draws attention, in that connection, to the key role played by AI and its potential as a driver of research and development in the health and pharmaceutical sector;
Amendment 64 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Urges to make the IP system more effective for SMEs, through actions to simplify IP registration procedures (e.g. reforming EU legislation on industrial designs), to improve access to strategic IP advice (e.g. by making such advice available in all EU-level R&D funding), and to facilitate the use of IP as a lever to gain access to finance;
Amendment 67 #
Draft opinion
Paragraph 4 b (new)
Paragraph 4 b (new)
4b. Stresses that investing in research and development is a costly, high-risk endeavour; underlines that patents are intended to offer some guarantee of a return on investment, but the patent system is also designed to balance the interests of inventors with those of the public; repeats therefore that pharmaceutical companies need intellectual property (IP) rights and thus patents to achieve profits and keep innovating also in the interest of the consumers and patients;
Amendment 83 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Notes that most of the time, radical innovation in the pharmaceutical sector is driven by SMEs (“biotechs”);
Amendment 85 #
Draft opinion
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Regrets that the EU is less attractive then other countries, such as the USA, in terms of pharmaceutical research and development which is mainly due to a financial environment which encourages more risk-taking by venture capital;
Amendment 86 #
Draft opinion
Paragraph 6 c (new)
Paragraph 6 c (new)
6c. Underlines the importance of a strong, efficient, transparent and balanced system of IP and trade secrets protection and the need for a coherent overall strategy to ensure both protection of – and fair access to – innovation to ensure that all companies established in the EU, including small and medium- sized ones, can effectively capitalise on their IP and make use of new technologies;
Amendment 89 #
Draft opinion
Paragraph 6 d (new)
Paragraph 6 d (new)
6d. Finally highlights that it is of outmost importance to speak with “a strong EU voice” on the global stage;